Analyst Conference Summaries |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
2seventy bio
|
2024 | |||
2seventy bio TSVT Q4 2023 |
2seventy bio TSVT Q1 2024 |
2seventy bio TSVT Q2 2024 |
|
March 5, 2024 | May 8, 2024 | Aug. 7, 2024 | |
2023 | |||
TSVT Q4 2022 Press Release |
2seventy bio TSVT Q1 2023 |
2seventy bio TSVT Q2 2023 |
2seventy bio TSVT Q3 2023 |
March 16, 2023 | May 3, 2023 | Aug. 14, 2023 | Nov. 14, 2023 |
2022 | |||
TSVT Q3 2022 Press Release |
|||
Nov. 7, 2022 |
2seventy bio (TSVT) is a biotechnology company specializing in CAR-T therapies.
More Analyst Conference Pages:
AGEN |
AGIO |
ALLO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BLRX |
BLUE |
BMY |
CLDX |
CDTX |
FATE |
GILD |
GLYC |
ILMN |
IMGN |
INCY |
INKT |
INO |
IONS |
MCHP |
MRNA |
PLX |
REGN |
RNA |
SAGE |
SANA |
SYRS |
VSTM |
VRTX |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers